Legal Representation
Attorney
Alyssa Worsham
USPTO Deadlines
Application History
50 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jun 16, 2022 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
Jun 16, 2022 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
Dec 3, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Dec 3, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Dec 3, 2021 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
Aug 30, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Aug 19, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Aug 17, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Aug 16, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
Aug 16, 2021 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
Aug 5, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
Aug 5, 2021 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
Aug 5, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Aug 5, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
Jan 22, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Jan 20, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
Jan 20, 2021 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
Jan 20, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jul 22, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Jul 20, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
Jul 20, 2020 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
Jul 20, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Feb 1, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Jan 30, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Jan 30, 2020 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Jan 30, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Oct 29, 2019 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
Oct 28, 2019 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
Oct 25, 2019 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Oct 23, 2019 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
Oct 23, 2019 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
Oct 3, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Oct 2, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Oct 2, 2019 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Aug 15, 2019 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
Aug 15, 2019 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION | Loading... |
Aug 15, 2019 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
Aug 15, 2019 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
Aug 5, 2019 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Feb 5, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Dec 11, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Dec 11, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Nov 21, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Nov 2, 2018 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Nov 2, 2018 | ALIE | A | ASSIGNED TO LIE | Loading... |
Oct 18, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Oct 15, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Oct 14, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Oct 14, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Aug 31, 2018 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | Loading... |
Detailed Classifications
Class 005
diagnostic reagents and instruments for medical or veterinary use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; diagnostic reagent kits comprising primarily of diagnostic reagents for medical or veterinary use in the fields of cancer, neurology and infectious disease; chemical reagents for medical use; reagents for medical or veterinary use containing antibodies and nucleic acids; diagnostic test kits for medical use comprising primarily reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical or veterinary diagnostic kits comprising medical or veterinary diagnostic reagents for use in detecting the presence of analytes in samples and identifying sample type, and equipment, namely, medical diagnostic immuno-assays for screening samples detecting the presence of analytes in samples and identifying sample type, sold as a unit with instructional manuals; diagnostic preparations in the nature of antibodies, for medical and veterinary purposes; reagents and diagnostic reagents for medical or veterinary purposes; diagnostic preparations in the nature of in situ hybridization probes, for medical and veterinary purposes; medical or veterinary diagnostic reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; multiparameter quantitative detection and analysis products and technology for diagnostics for a variety of uses in health care, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents and assays for testing of body fluids or tissue; kits consisting primarily of medical or veterinary diagnostic reagents and assays for testing of body fluids or tissue; reagents in the form of cell markers and molecule markers including antibodies and nucleic acids for medical or veterinary purposes; medical diagnostic reagents for use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents for use relating to molecular identification and digital quantification; medical diagnostic reagents containing antibodies and nucleic acids; medical diagnostic reagents for use in the fields of cancer, neurology and infectious disease; medical diagnostic reagents for immuno-histochemistry detection and in situ-hybridization detection; medical diagnostic reagents for use relating to molecular identification and digital quantification
First Use Anywhere:
Sep 5, 2018
First Use in Commerce:
Sep 5, 2018
Classification
International Classes
005